Lumos Pharma Inc

NASDAQ:LUMO   3:41:22 PM EDT
4.83
-0.34 (-6.58%)
Regulatory, Earnings Announcements

Lumos Pharma Announces Encouraging Interim Mid-stage Study Results For Pediatric Growth Drug

Published: 11/14/2022 11:20 GMT
Lumos Pharma Inc (LUMO) - Lumos Pharma Announces Encouraging Interim Results From Two Phase 2 Trials Evaluating Oral Lum-201 for Moderate Pediatric Growth Hormone Deficiency.
Lumos Pharma Inc - Lum-201 Met Expectations in Interim Analysis of Two Phase 2 Trials Evaluating Growth in Pediatric Growth Hormone Deficiency (pghd).
Lumos Pharma - Interim Results for About 50% Enrollment of Oragrowth210 Trial Showed Mean Ahv of 8.6 Cm at Six Months for 1.6 Mg/kg/day Lum-201.
Lumos Pharma Inc - Data Further De-risk Clinical Program and Support Selection of 1.6 Mg/kg/day Lum-201 Dose for Pivotal Phase 3 Trial.
Lumos Pharma Inc - Continues to Anticipate Primary Outcome Readout With All 80 Subjects at Six Months in 2h 2023 From Oragrowth210 Trial.
Revenue is expected to be $0.11 Million
Adjusted EPS is expected to be -$0.93

Next Quarter Revenue Guidance is expected to be $0.1 Million
Next Quarter EPS Guidance is expected to be -$0.93

More details on our Analysts Page.